JP2007525183A5 - - Google Patents

Download PDF

Info

Publication number
JP2007525183A5
JP2007525183A5 JP2006514206A JP2006514206A JP2007525183A5 JP 2007525183 A5 JP2007525183 A5 JP 2007525183A5 JP 2006514206 A JP2006514206 A JP 2006514206A JP 2006514206 A JP2006514206 A JP 2006514206A JP 2007525183 A5 JP2007525183 A5 JP 2007525183A5
Authority
JP
Japan
Prior art keywords
antibody
protein
seq
polynucleotide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013568 external-priority patent/WO2004098515A2/en
Publication of JP2007525183A publication Critical patent/JP2007525183A/ja
Publication of JP2007525183A5 publication Critical patent/JP2007525183A5/ja
Pending legal-status Critical Current

Links

JP2006514206A 2003-04-30 2004-04-30 癌の処置および検出において有用な109p1d4と称される、核酸および対応タンパク質 Pending JP2007525183A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46700203P 2003-04-30 2003-04-30
PCT/US2004/013568 WO2004098515A2 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011023063A Division JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な109p1d4と称される、核酸および対応タンパク質

Publications (2)

Publication Number Publication Date
JP2007525183A JP2007525183A (ja) 2007-09-06
JP2007525183A5 true JP2007525183A5 (enExample) 2007-10-18

Family

ID=33435005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006514206A Pending JP2007525183A (ja) 2003-04-30 2004-04-30 癌の処置および検出において有用な109p1d4と称される、核酸および対応タンパク質
JP2011023063A Pending JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な109p1d4と称される、核酸および対応タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011023063A Pending JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な109p1d4と称される、核酸および対応タンパク質

Country Status (5)

Country Link
EP (1) EP1622571A4 (enExample)
JP (2) JP2007525183A (enExample)
AU (2) AU2004235755A1 (enExample)
CA (1) CA2522994C (enExample)
WO (1) WO2004098515A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
EA014886B1 (ru) * 2006-03-31 2011-02-28 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
AU2020226723B2 (en) 2019-02-22 2025-01-23 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-
MA55593A (fr) 2019-04-11 2022-02-16 Janssen Pharmaceutica Nv Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572987A4 (en) * 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Similar Documents

Publication Publication Date Title
JP2007525183A5 (enExample)
JP6182127B2 (ja) 腫瘍において示差的に発現する遺伝子産物およびその利用
JP6223488B2 (ja) 腫瘍で差次的に発現する遺伝子産物及びその用途
RU2627176C2 (ru) Новые модуляторы и способы их применения
RU2592672C9 (ru) Новые модуляторы и способы их применения
CN105837689B (zh) 抗cd19单克隆抗体及其制备方法
CA2395053A1 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
JP6586648B2 (ja) 抗プログルカゴン抗体
JP2016094485A (ja) 新規モジュレータ及びその使用法
US20190194345A1 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
US9453070B2 (en) Methods for detecting Th1 cells
WO2000053758A2 (en) Compositions and methods for the treatment of immune related diseases
JP2014528714A5 (enExample)
Fry et al. CD22-CAR T cells induce remissions in CD19-CAR naïve and resistant B-ALL
JP2007504280A5 (enExample)
US9683032B2 (en) Anti-S100A4 antibody molecules and their uses
CN102753579A (zh) 抗钙粘着蛋白抗体
CN112795543B (zh) 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
JP2006519774A (ja) 癌の治療のための組成物と方法
CN105646712B (zh) 单克隆抗体及其应用
JP4423006B2 (ja) 肝幹細胞の検出又は分離方法
Bao et al. Cloning, expression, monoclonal antibody preparation of human gene NBEAL1 and its application in targeted imaging of mouse glioma
WO2012160031A1 (en) Method for prognosing solid tumor outcome
WO2010123119A1 (ja) 炎症性腸疾患治療剤およびそのスクリーニング方法
JP2008532923A (ja) 抗gfra1抗体のエフェクター機能を用いて細胞を障害する方法